Visualisation of a Digital Care Pathway.
Visualisation of a Digital Care Pathway in Limburg, in Context of Digital Care Support as a Stepping Stone for Flanders.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Good quality of care requires a multidisciplinary approach, especially with chronic illnesses. Therefore, all members of the care team should be adequately informed and communicate well with each other. Additionally, patients should have a key role in their treatment plan. To successfully optimize self care, patients have to be well-informed about pathogenesis, treatments and complications so that expectations are realistic and attainable goals can be set. Currently, access to this relevant data is fragmented and often unavailable.
The newly developed application creates a central platform where all relevant data, educational material, medication scheme... are available for both the patient and healthcare professionals. The targeted study population are patients with type 2 diabetes who will be recruited by their general practitioner (GP) over a period of 3 months. When patients are interested in partaking, they will be contacted by a healthcare professional who will function as a Single Point of Contact (SPOC) for the patient during the entirety of the study with a maximum duration of 6 months. The SPOC helps with the start up of the application, collects administrative data and contacts the participants at regular intervals to help with difficulties in using the application. Furthermore, the SPOC will administer a questionnaire determining patient involvement and experience at the start and end of the study, as well as conduct an in-depth interview when the study is completed. Throughout the study, other questionnaires will be digitally available for the patient as part of the care path. These patient reported outcome and experience measures (PROM/PREM) will support healthcare professionals in providing a more integral care.
Consequently, involved healthcare professionals will also be contacted, informed and asked to complete a questionnaire once healthcare professionals agree to participate in the study. This questionnaire will focus on the information and communication needs between members of the care team and will also be repeated at the end, followed by an in-depth interview.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Emilie Weyens
- Número de teléfono: +32 11 33 51 17
- Correo electrónico: emilie.weyens@jessazh.be
Copia de seguridad de contactos de estudio
- Nombre: Jolien Nelissen, Dr
- Número de teléfono: +32 11 33 51 18
- Correo electrónico: jolien.nelissen@jessazh.be
Ubicaciones de estudio
-
-
Limburg
-
Hasselt, Limburg, Bélgica, 3500
- Reclutamiento
- Jessa Hospital
-
Contacto:
- Emilie Weyens
- Correo electrónico: emilie.weyens@jessazh.be
-
Contacto:
- Jolien Nelissen, Dr.
- Correo electrónico: jolien.nelissen@jessazh.be
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria for cohort 1 and 2:
- patients with type 2 diabetes (voortraject and zorgtraject)
- independent and mentally competent
- digitally literate and in possession of an email address
- mastered the Dutch language
- able to visit the GP (no house calls)
Additional inclusion criteria for cohort 2 :
- presence of a home nurse in the context of the Diabetes care
- presence of a home care service
Exclusion Criteria:
- patients type 2 Diabetes enrolled in the Diabetes convention
- pregnant patients
- illiterate people
- patients living in a residential care center
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: patients
Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale. Post measurement: questionnaire quantifying patient involvement and experience on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview. |
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team.
The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records.
The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement.
Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
|
|
Experimental: healthcare professionals
Implementation and visualisation of digital care path. Pre measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale. Post measurement: questionnaire quantifying communication needs and experiences on a 5-p Likert scale, questionnaire quantifying usability of the tool and in-depth interview. |
The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team.
The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records.
The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement.
Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in patient empowerment and involvement
Periodo de tiempo: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
|
Change in care team communication and sharing of data
Periodo de tiempo: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
|
Usability and acceptance of the application in patients and healthcare professionals
Periodo de tiempo: For a minimum of 12 weeks
|
Primary outcome measures will be determined with the aid of a questionnaire scoring answers on a 5p-Likert scale. Due to limited availability of validated questionnaires in Dutch, a custom set of questions was generated. Starting from validated English questionnaires on each topic, the Delphi method was used to reach consensus in selecting the final questions. At the end of the study, an in-depth interview will take place with a predefined topic list. |
For a minimum of 12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
User characteristics of the application.
Periodo de tiempo: for a minimum of 12 weeks
|
Data will be collected from logs, available in the back office of the application
|
for a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: HbA1c
Periodo de tiempo: for a minimum of 12 weeks
|
HbA1c will be expressed in %
|
for a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: blood pressure
Periodo de tiempo: For a minimum of 12 weeks
|
Both systolic and diastolic blood pressure will be measured, expressed in mmHg.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: glycemia
Periodo de tiempo: For a minimum of 12 weeks
|
Glycemia will be expressed in mg/dl.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: girth
Periodo de tiempo: For a minimum of 12 weeks
|
Girth will be expressed in cm.
|
For a minimum of 12 weeks
|
|
Possible change,impact on personal clinical parameters: bodyweight
Periodo de tiempo: For a minimum of 12 weeks
|
Weight will be expressed in kg.
|
For a minimum of 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Yves Breysem, Dr, Jessa Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 2021/036
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .